Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer

18 Sept 2020

Abstract excerpt

Abstract Lung cancer is still the leading cause of death by cancer worldwide despite advances both in its detection and therapy. Multiple oncogenic driver alterations have been discovered, opening the prospective for new potential therapeutic targets. Among them, KRAS mutations represent the most frequent oncogene aberrations in non-small cell lung cancer (NSCLC) patients with a negative prognostic impact, but...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Treatments and Mutations
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32948832
DOI: 10.1038/s41417-020-00224-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancerPMID 32948832Read ↗

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.Semantic proximity Read ↗

Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.Semantic proximity Read ↗

MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancerSemantic proximity Read ↗

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancerSemantic proximity Read ↗

WEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.Semantic proximity Read ↗

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung CancersSemantic proximity Read ↗

KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.